Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency Copenhagen, Denmark, May 31, 2024  – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

Press release – No. 5 / 2024 Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

Company announcement – No. 28 / 2024 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark, 29 May 2024  – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma major shareholder announcement: Polar Capital

Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean weight loss of up to 4.3% after 12 weeks with low doses of dapiglutide treatment Dapiglutide was assessed to be well-tolerated Tolerability profile observed suggests doses investigated were at the lower end of the therapeutic range Much higher doses of dapiglutide are being investigated in the ongoing 13-week Phase 1b trial, with topline results expected in the second half 2024 Copenhagen, Denmark, 23 May 2024  – Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no.

Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

Company announcement - No. 26 / 2024 Zealand Pharma Announces Financial Results for the First Quarter of 2024 Strong performance in the first quarter of 2024 paving the way for important data read-outs across differentiated obesity assets in the second quarter.

Zealand Pharma Announces Financial Results for the First Quarter of 2024

Press Release – No. 4 / 2024 Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results Copenhagen, Denmark, May 9, 2024 – Zealand Pharma A/S (CVR-no.

Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results

Correction to Company announcement – No. 23 / 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.

Correction to Company announcement – No. 23 / 2024

Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and employees for 2024

Company announcement – No. 17 / 2024 Zealand Pharma's Annual General Meeting 2024 Copenhagen, March 20, 2024 - Today, Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR no.

Zealand Pharma's Annual General Meeting 2024

Company announcement – No. 14 / 2024 New Employee Elected Directors to the Board of Zealand Pharma A/S Copenhagen, Denmark, March 13, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.

New Employee Elected Directors to the Board of Zealand Pharma A/S

Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen's 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.

Zealand Pharma to Participate in TD Cowen's 44th Annual Health Care Conference

Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript

Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a solid financial position Positive results achieved for petrelintide in 6-week Phase 1 trial and clinical advancement of dapiglutide and petrelintide towards obesity data readouts in 2024 Positive results announced in Boehringer Ingelheim Phase 2 clinical trials for survodutide in obesity and global Phase 3 clinical program in obesity initiated NDA submissions for dasiglucagon in congenital hyperinsulinism and glepaglutide in short bowel syndrome expected to support regulatory decisions for rare diseases in 2024 Private placement of shares to institutional investors, European Investment Bank loan facility, undrawn committed RCF and milestone payments from existing partners contribute to strengthened financial position Events after the reporting period Positive results announced in Boehringer Ingelheim Phase 2 clinical trial for survodutide in MASH and private placement of shares to institutional investors contribute to extended cash runway into 2027 Copenhagen, Denmark, February 27, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma Announces Financial Results for the Full Year 2023

Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase 2 trial Survodutide, a novel glucagon/GLP-1 receptor dual agonist, has demonstrated efficacy in people with obesity, and statistically significant results in MASH suggest the potential to lead to clinically meaningful benefits across the cardiovascular, renal, and metabolic spectrum Full data from the Phase 2 trial will be presented in the coming months Copenhagen, Denmark, February 26, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) today announced that Boehringer Ingelheim has reported that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase 2 trial [response difference: 64.8% (CI 51.1% - 78.6%), p-value (p

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand Pharma A/S (CVR-no.

Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results

Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024  – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024  – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC

Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.

Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion

Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand Pharma A/S (CVR-no.

Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th

Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility The CRL is related to deficiencies identified at a third-party manufacturing facility following an inspection but are not specific to dasiglucagon.

U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility

Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no.

Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome

Press release No. 17 / 2023 Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank Copenhagen, Denmark, December 22 , 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no.

Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank

Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and clinical experts Copenhagen, Denmark, December 4, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no.

Zealand Pharma to highlight obesity pipeline at R&D Event on December 5

Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no.

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

Zealand Pharma A/S (ZEAL) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Anna Krassowska - Vice President-Investor Relations Adam Steensberg - President & Chief Executive Officer David Kendall - Chief Medical Officer Henriette Wennicke - Chief Financial Officer Conference Call Participants Michael Novod - Nordea Lucy Codrington - Jefferies Rajan Sharma - Goldman Sachs Charlie Mabbutt - Morgan Stanley Anna Krassowska Welcome, and thank you for joining us to discuss Zealand's interim results for the first nine months of 2023. With me today are the following members of Zealand's management team, Adam Steensberg, President and Chief Executive Officer; Henriette Wennicke, Chief Financial Officer; and David Kendall, Chief Medical Officer.

News for Zealand Pharma Stock (ZEAL)